The Novavax COVID-19 vaccine, sold under the brand names Nuvaxovid and Covovax, among others, is a subunit COVID-19 vaccine developed by Novavax and the Coalition for Epidemic Preparedness Innovations. From Wikipedia
The protein-based vaccine is now approved for adults 65+ and high-risk individuals aged 12–64, with new trials required to assess heart risks and deferred pediatric studies.
